Meulders Q, Pirson Y, Cosyns J P, Squifflet J P, van Ypersele de Strihou C
Department of Nephrology, Cliniques Universitaires St. Luc, Brussels, Belgium.
Transplantation. 1994 Dec 15;58(11):1179-86.
The frequency and the risk factors for clinical recurrence of Henoch-Schönlein nephritis following renal transplantation (TP) remain largely unknown. We report on 14 transplants performed at our center in 10 patients, detail the evolution of 2 of them with clinical recurrence, and review 64 other transplants reported in the literature. In our series, all patients are currently alive. Seven grafts are well-functioning 22-295 (mean, 97) months after TP without any sign of clinical recurrence. Five grafts were lost from rejection. Clinical recurrence occurred in 2 patients who were on cyclosporine/azathioprine/prednisone therapy. Pooling our series with that of Hasegawa et al., the actuarial risk for renal recurrence and for graft loss due to recurrence was 35 and 11% at 5 years after TP, respectively. In our series, duration of original disease was 2 and 28 months in the 2 patients with recurrence versus 31-144 months in the others without recurrence. In the literature, this duration was < or = 36 months in all 7 patients with recurrence. Recurrence occurred despite a > 12-month delay between disappearance of purpura and TP in our 2 patients and in 3 of 6 previously reported recurrences. We conclude that Henoch-Schönlein purpura nephritis frequently recurs after TP. Recurrence (1) seems to be associated with a shorter duration of the original disease, (2) can occur despite a delay of more than 1 year (as commonly advised) between disappearance of purpura and TP, and (3) is not prevented by a triple immunosuppressive regimen that includes cyclosporine.
肾移植(TP)后过敏性紫癜性肾炎临床复发的频率及危险因素在很大程度上仍不清楚。我们报告了在我们中心为10例患者实施的14例移植手术,详细描述了其中2例临床复发患者的病情演变,并回顾了文献中报道的其他64例移植手术。在我们的系列研究中,所有患者目前均存活。7例移植肾在TP后22 - 295(平均97)个月功能良好,无任何临床复发迹象。5例移植肾因排斥反应而丧失功能。2例接受环孢素/硫唑嘌呤/泼尼松治疗的患者发生了临床复发。将我们的系列研究与长谷川等人的研究合并后,TP后5年肾复发和因复发导致移植肾丧失的精算风险分别为35%和11%。在我们的系列研究中,2例复发患者的原发病病程为2个月和28个月,而其他未复发患者的病程为31 - 144个月。在文献中,所有7例复发患者的病程均≤36个月。在我们的2例患者以及之前报道的6例复发患者中的3例中,尽管紫癜消失至TP之间间隔超过12个月,但仍发生了复发。我们得出结论,过敏性紫癜性肾炎在TP后经常复发。复发(1)似乎与原发病病程较短有关,(2)尽管紫癜消失至TP之间间隔超过1年(如通常所建议的)仍可能发生,(3)不能通过包括环孢素在内的三联免疫抑制方案预防。